Gliotoxin, a known virulence factor in the major human pathogen Aspergillus fumigatus, is 3 also biosynthesized by the non-pathogenic relative A. fischeri 4 5 ABSTRACT 21
mycotoxin known to contribute to A. fumigatus virulence. We discovered that the non-48 pathogenic A. fischeri produces gliotoxin under the same conditions as the major pathogen A. 49 fumigatus. However, we also discovered that, in contrast to what has been previously observed in 50
A. fumigatus, loss of secondary metabolite, including gliotoxin, production in A. fischeri does not 51 alter its virulence. Our results are consistent with the "cards of virulence" model of opportunistic 52 fungal disease, where the ability to cause disease stems from the combination ("hand") of 53 individual virulence factors ("cards"), but not from individual factors per se. 54
Aspergillus fumigatus is a major fungal pathogen responsible for hundreds of thousands of 55 infections and deaths each year (1, 2) . Several secondary metabolites biosynthesized by A. 56 fumigatus have been shown to be required for disease (3). For example, gliotoxin (Fig. 1A) , a 57 secondary metabolite that belongs to the epipolythiodioxopiperazine (ETP) class of mycotoxins 58
(4), can be detected in the sera of patients with invasive aspergillosis (5) and is known to inhibit 59 the host immune response (3). When the gliP gene, which encodes the major synthetase of the 60 gliotoxin biosynthetic gene cluster, is deleted from A. fumigatus, the mutant strain does not 61 biosynthesize gliotoxin and exhibits attenuated virulence in a non-neutropenic murine model of 62 aspergillosis (6) (7) (8) . Similarly, deletion of laeA, a positive regulator of several A. fumigatus 63 secondary metabolites, including gliotoxin, also reduces virulence (9, 10). These results establish 64 that gliotoxin, as well as other secondary metabolites, contribute to A. fumigatus virulence (3). 65 66 Even though A. fumigatus is a major pathogen, its closest relatives are non-pathogenic (11) (12) (13) . 67
For example, the closely related species Aspergillus fischeri has been identified as the cause of 68 only a handful of clinical cases (14, 15) and is not considered pathogenic. Detailed comparisons 69 of virulence in diverse murine and invertebrate models of fungal disease have shown that A. 70 fischeri is much less virulent than A. fumigatus (12). It is important to emphasize here that in 71 diverse animal models of aspergillosis, especially when high inoculums of spores are 72 administered, non-pathogens can sometimes cause disease, as we have observed in previous 73 experiments with A. fischeri; however, in all such cases non-pathogens exhibit lower levels of 74 virulence than pathogens (12). 75 76 Despite their significant differences in ability to cause fungal disease, a recent examination of 77 known genetic contributors to virulence revealed that nearly all genes known to contribute to A. 78 fumigatus disease are also present in A. fischeri (12) . For example, both species appear to contain 79 laeA, and deletion of the laeA gene in either species is known to reduce biosynthesis of 80 secondary metabolites (12, 16 ), suggesting that the gene's function is conserved. Similarly, both 81 species appear to contain intact gliotoxin biosynthetic gene clusters (Fig. 1B) ; however, gliotoxin 82 production has been shown in A. fumigatus and a few other closely related species (17), but not 83 in A. fischeri (12, 17) . These data raise two questions: Is A. fischeri capable of biosynthesizing 84 gliotoxin? And if it is, how does production of gliotoxin, and secondary metabolites more 85 generally, influence its virulence profile? 86 87 A. fischeri, a non-pathogenic relative of the major pathogen A. fumigatus, can also 88 biosynthesize gliotoxin.
To test whether A. fischeri biosynthesizes gliotoxin, we examined 89 the chemical profile of a standard of gliotoxin and extracts of A. fumigatus strain Af293, and A. 90 fischeri strain NRRL 181 via UHPLC-HRESIMS (ultra-high-performance liquid 91 chromatography-high-resolution electrospray ionization mass spectrometry) (Supplementary 92 Methods). We collected three sets of data, specifically chromatographic retention time, high 93 resolution mass spectrometry data, and tandem mass spectrometry fragmentation patterns. 94
Analysis of a gliotoxin standard (Fig. 1C) We next analyzed A. fumigatus strain Af293, which we used as a positive control, since it is 99 known to biosynthesize gliotoxin (17). When A. fumigatus was grown on Czapek-Dox Agar 100 (CDA) at 37°C (Fig. 1D) , a peak with the same retention time (3.30 min), HRESIMS spectrum, 101 MS/MS spectrum, and accurate mass of 327.0463 (3.1ppm) was noted (Figs. S1 and S2). We 102 also detected gliotoxin production, albeit in lower abundance, when we cultured A. fumigatus on 103 5% blood agar at 37°C (Fig. 1E) . In contrast, we did not observe gliotoxin production when we 104 grew A. fumigatus on oatmeal agar at 37°C (Fig. S3) . To test whether A. fischeri biosynthesized gliotoxin, we grew strain NRRL 181 on the same 128 media and temperature conditions as A. fumigatus. When A. fischeri was grown on CDA at 37°C, 129
we observed a peak with the same retention time (Fig. 1F) , HRESIMS spectrum (Fig. S4) , and 130 MS/MS spectrum as that of A. fumigatus (Fig. S5) , indicating gliotoxin biosynthesis in A. 131 fischeri. Similarly, we detected gliotoxin production in lower abundance when we grew A. 132 fischeri on 5% blood agar at 37 o C (Fig. 1G) . In contrast, we did not observe gliotoxin production when we grew A. fischeri on CDA or on 5% blood agar at room temperature ( Figs. 1H and 1I,  134 respectively) or on oatmeal agar at 37 o C (Fig. S3) . These results demonstrate that: a) the non-135 pathogen A. fischeri biosynthesizes similar quantities of gliotoxin in the same conditions that 136 induce gliotoxin biosynthesis in the major pathogen A. fumigatus, and b) similar to what has 137 been previously observed in A. fumigatus (20), both growth medium and temperature influence 138 gliotoxin biosynthesis in A. fischeri. 139 140 laeA, a master regulator of secondary metabolism and A. fumigatus virulence factor, is not 141 a virulence factor in A. fischeri. To test whether the regulation of gliotoxin production, and 142 more generally of secondary metabolite production, contributes to the virulence profile of A. 143 fischeri, we deleted the endogenous copy of laeA from A. fischeri and infected larvae of the moth 144
Galleria mellonella, a well-established invertebrate model of fungal disease (21), with the 145 resulting mutant strain (Supplementary Methods) . Infection of G. mellonella larvae with A. 146 fumigatus is known to induce gliotoxin biosynthesis (22). We infected asexual spores (conidia) at 147 two different concentrations and compared the survival curves between the Δ laeA and the wild-148 type (WT) strain of A. fischeri (Fig. 2) . At both concentrations, our experiments showed that 149 moth larval survival was not significantly different between the Δ laeA and the WT strains. WT strain revealed no statistically significant differences at spore concentrations of 5 x 10 5 (left) 158 or 1 x 10 6 (right) (p-value = 0.91 and 0.30, respectively; log-rank test). For the inoculations, ten 159 moths were infected per group. 160
Importantly, the Δ laeA strain of A. fischeri NRRL 181 is known to exhibit reduced production of 163 secondary metabolites in diverse conditions in a manner consistent with the gene's role as a 164 master regulator of secondary metabolism (12). To confirm that the Δ laeA strain does not 165 produce gliotoxin, we analyzed it using the same chemical methods that showed production of 166 gliotoxin in the WT strain following growth on CDA or 5% blood agar at 37 o C. In contrast to the 167 WT strain (Figs. 1F and 1G) , we did not observe gliotoxin production in the Δ laeA strain (Fig.  168   S3) . Whereas loss of laeA and secondary metabolite -including gliotoxin -production has been previously shown to reduce the virulence of the major pathogen A. fumigatus (9, 10), our results 170 suggest that loss of laeA (and secondary metabolite production, including gliotoxin) in A. fischeri 171 does not influence its virulence. 172
173
Concluding remarks.
In this study, we show for the first time that A. fischeri -when 174 grown in conditions known to induce gliotoxin production in A. fumigatus -can biosynthesize 175 gliotoxin (Fig. 1) . Furthermore, we show that an A. fischeri mutant that lacks a master regulatory 176 gene of secondary metabolism (laeA) does not alter the pathogenic potential of A. fischeri (Fig.  177 2). Thus, it appears that gliotoxin and secondary metabolite production more generally are 178 virulence factors in the genomic and phenotypic background of the pathogen A. fumigatus but 179 that they are much less important for virulence in the genomic background of the non-pathogen 180 A. fischeri. These results provide support for the "cards of virulence" model of opportunistic 181 fungal disease (23), where the ability to cause disease stems from the combination ("hand") of 182 individual virulence factors ("cards"). We hypothesize that while A. fischeri possesses the 183 "cards" for gliotoxin production and secondary metabolism regulation, its cumulative "hand" is 184 thankfully not a winner when it comes to causing disease. A. fischeri grown on blood agar at 37°C show that some media do not induce gliotoxin 201 biosynthesis. 202
